Advertisement
UK markets close in 3 hours 54 minutes
  • FTSE 100

    8,083.41
    +38.60 (+0.48%)
     
  • FTSE 250

    19,799.49
    -0.23 (-0.00%)
     
  • AIM

    754.81
    -0.06 (-0.01%)
     
  • GBP/EUR

    1.1637
    +0.0009 (+0.08%)
     
  • GBP/USD

    1.2436
    -0.0016 (-0.13%)
     
  • Bitcoin GBP

    53,525.02
    +387.14 (+0.73%)
     
  • CMC Crypto 200

    1,434.32
    +10.22 (+0.72%)
     
  • S&P 500

    5,070.55
    +59.95 (+1.20%)
     
  • DOW

    38,503.69
    +263.71 (+0.69%)
     
  • CRUDE OIL

    82.80
    -0.56 (-0.67%)
     
  • GOLD FUTURES

    2,328.60
    -13.50 (-0.58%)
     
  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     
  • HANG SENG

    17,201.27
    +372.34 (+2.21%)
     
  • DAX

    18,184.96
    +47.31 (+0.26%)
     
  • CAC 40

    8,132.22
    +26.44 (+0.33%)
     

Exploring Voyager Therapeutics’ Cash Flows and Valuation Metrics

Exploring Voyager Therapeutics’ Cash Flows and Valuation Metrics

Voyager Therapeutics (VYGR) spent $61.3 million on operating activities in 2017 compared to $42.4 million in 2016. In comparison, it generated $47.3 million from investing activities in 2016. The company’s positive investing cash flow in 2016 was attributable to proceeds from the maturities of marketable securities of $165.1 million, and it was partially offset by securities purchases of $112.4 million.